News | February 10, 2024
Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Subscribe To Our Newsletter & Stay Updated
